The company said Catheter-associated urinary tract infection (CAUTIs) is a leading cause of nosocomial complications affecting patient’s morbidity and mortality. And prolonged urinary catheterization can significantly increase the cost of medical care.
NanoVibronix claims that UroShield system is a multi-targeting solution which has been designed to work counter a number of factors that are essential in preventing catheter related complications.
It also says that UroShield can control pain and discomfort of using a urinary catheter and can also decrease catheter related trauma, inhibits bacteriuria by preventing the formation of biofilm and increase the effectiveness of antibiotics.
NanoVibronix CEO William Stern said: "We are very pleased with Health Canada's approval to sell the UroShield in Canada. There are millions of urinary catheters used in hospitals every year.
“Most patients who have a chronic need for indwelling catheters will get infected with a UTI after a few weeks. In addition, patients who have indwelling catheters as part of surgical procedures in hospitals also suffer the same risk.
“UTIs are generally difficult to manage, however the UroShield not only prevents UTIs but also reduces the pain associated with urinary catheters.
William Stern also said that the company is presently conducting double blind trial for UroShield in US to receive 510(k) clearance from the U.S. Food and Drug Administration.
NanoVibronix is a medical device company with its headquarters in New York, US and research and development centre in Israel. The company produces medical devices which use low intensity surface acoustic wave technology.
